Interestingly, we observed ANGPTL2 production in heart of ∼40% of DCM patients tested here, suggesting that cardiac dysfunction may be worsened by ANGPTL2 activity and that this subset of patients might be candidates for therapeutic ANGPTL2 suppression. Here, ANGPTL2 is linked to familial dilated cardiomyopathy.